2012
FlexGen, Beijing Genomics Institute and LUMC collaborate in Target Enrichment – 25 January 2012
Agentschap NL features FlexGen as the success story of the arrayvolution eurostars program – 20 January 2012
2011
arGEN-X is awarded €1.3 million IWT Grant – 19 December 2011
Arcarios supported by Agentschap NL to accelerate the development of its disease modifying osteoarthritis drug - 8 December 2011
arGEN-X raises EUR 27.5 Million in oversubscribed Series B round – 1 December 2011
Arcarios receives IWT grant – 16 November 2011
Mucosis Announces New Scientific Advisory Board – 15 November 2011
FlexCalc NGS cost calculator and FleXelect oligopools featured in INsequence – 21 September 2011
Argen-X Announces Non-Exclusive License with Biowa for Potelligent® Technology – 26 July 2011
Mucosis appoints Thomas Johnston as Chief Business Officer – 17 May 2011
BioGeneration Announces Closing of BioGeneration Ventures II – 10 May 2011
Mucosis starts clinical study with its lead product, Flugem™ - 21 March 2011
Medisse appoints Alexander Vos to supervisory board - 7 March 2011
BioGeneration Ventures Announces Second Exit – 17 February 2011
Bioceros awarded Eurostars grant – 12 January 2011
arGEN-X signs discovery and development alliance with Lilly - 5 January 2011
2010
arGEN-X appoints Dr Debbie Allen as Senior Director Business Development – 15 November 2010
Dr Barry Buckland joins the Mucosis Supervisory Board - 12 November 2010
Mucosis and PATH sign agreement to pursue Mimopath™-based oral diarrhea vaccines – 28 Sept 2010
Seasoned pharma and vaccine industry executive John Lambert elected chairman of Mucosis – 23 September 2010
Arcarios B.V. announces final closing of EUR 4.1 M seed-financing round – 8 September 2010
BioGeneration leads large syndicate in first round investment in Arcarios BV - 25 August 2010
TiGenix announces spin-out of its targeted drug discovery activities in newco Arcarios - 24 August 2010
BioCeros and Prima Biomed (AUS) announce licensing agreement for Cripto-1 cancer immunotherapy treatment - 17 August 2010
arGEN-X granted broad patent covering its unique SIMPLE Antibody™ platform – 8 July 2010
Mucosis receives financial support from the Dutch government for its FluGEM™program – 31 May 2010
Foundation Mibiton finances sequencing apparatus of FlexGen (Dutch) – 15 May 2010
Mucosis appoints Dr. Roberto Grimaldi as Chief Medical Officer – 27 April 2010
2009
Medisse announces closure of a financing round by BioGeneration Ventures and Crédit Agricole Private Equity - 10 December 2009
Mucosis receives key US patent covering its Mimopath (tm) Technology - 22 September 2009
arGEN-X raises €9.5 million to put SIMPLE Antibody™ platform to work - 10 September 2009
FlexGen announced today the closure of an equity financing round by BioGeneration Ventures and Crédit Agricole Private Equity - 2 March 2009
DSM and Crucell Sign Agreement with Bioceros ... - 10 February 2009
Mucosis B.V. and PATH start development of pneumococcal vaccines - 28 January 2009
Progentix Orthobiology and NuVasive Sign Investment Agreement - 14 January 2009
NuVasive Announces Investment in Novel Orthobiologic Company - 13 January 2009
2008
Mucosis B.V. and TNO announce flu vaccine research and development partnership - 15 December 2008
Mucosis B.V. appoints Dr. Govert Schouten as CEO - 6 November 2008
Bioceros B.V. closes first financing round - 21 September 2008
Progentix Orthobiology B.V. closes Series A financing round - 21 January 2008
NovioGendix closes Series A Financing Round - 21 January 2008
2007
Mucosis raises € 3 million in first financing round - 10 September 2007
Forbion Capital Partners spins out of ABN AMRO Capital - 08 January 2007
2006
First closing of BioGeneration Ventures Fund - 17 November 2006
|
